Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on December 7, 2016. The filing discloses the completion of a private placement of senior secured convertible notes and a concurrent exchange agreement with existing noteholders.
Key Financial Metrics and Capital Structure
- New Debt Issuance: The Company sold $22.5 million aggregate principal amount of 7.50% Senior Secured Convertible Notes due 2021 ("New Money Notes").
- Debt Exchange: The Company exchanged $54.052 million of outstanding 4.50% Convertible Senior Notes due 2018 for:
- $40.186 million aggregate principal amount of new 7.50% Senior Secured Convertible Notes due 2021 ("Exchange Notes").
- 23,846,735 shares of common stock (valued at $0.5595 per share).
- Cash payment for accrued and unpaid interest and fractional shares.
- Total New Notes: The combined principal amount of New Money Notes and Exchange Notes is $62.686 million.
- Interest Rate: 7.50% per annum, payable semi-annually. The Company may elect to pay up to 1.25% per annum in common stock.
- Maturity: November 15, 2021.
- Collateral: The Notes are secured by perfected liens on all of the Company's material assets.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or revenue/profit metrics. The primary material change is the restructuring of the Company's debt profile:
- Replacement of $54.052 million in unsecured 4.50% notes due 2018 with secured 7.50% notes due 2021.
- Extension of debt maturity from 2018 to 2021.
- Significant dilution through the issuance of approximately 23.8 million shares of common stock.
- Increased interest expense rate from 4.50% to 7.50% on the exchanged portion.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operations. Key risks and contingencies identified include:
- Secured Debt: The new notes are secured by all material assets, increasing the risk of asset liquidation in the event of default.
- Unregistered Securities: Neither the Notes nor the common stock issued upon conversion are registered under the Securities Act.
- Interest Payment Flexibility: The Company has the option to pay a portion of interest in stock, which may lead to further dilution.
Investor Verification Checklist
- Verify the exact cash proceeds received from the $22.5 million New Money Notes after deducting any transaction fees or discounts.
- Confirm the total number of outstanding shares post-issuance to assess the full dilution impact of the 23.8 million shares issued in the exchange.
- Review the full text of the Indenture (Exhibit 4.1) and Security Agreements (Exhibits 10.3 and 10.4) to understand specific covenants and default triggers.
- Assess the Company's current cash runway given the increased interest obligation (7.50% vs. 4.50%) and the lack of disclosed operating revenue in this filing.